The Vanguard Group 13D and 13G filings for Deciphera Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:02 pm Sale |
2023-12-29 | 13G | Deciphera Pharmaceuticals, Inc. DCPH |
The Vanguard Group | 4,401,636 5.490% |
-343,685 (-7.24%) |
Filing |
| 2023-02-09 11:16 am Purchase |
2022-12-30 | 13G | Deciphera Pharmaceuticals, Inc. DCPH |
The Vanguard Group | 4,745,321 7.020% |
1,276,004 (+36.78%) |
Filing |
| 2022-02-09 3:43 pm Sale |
2021-12-31 | 13G | Deciphera Pharmaceuticals, Inc. DCPH |
The Vanguard Group | 3,469,317 5.930% |
-366,441 (-9.55%) |
Filing |
| 2021-02-10 10:46 am Purchase |
2020-12-31 | 13G | Deciphera Pharmaceuticals, Inc. DCPH |
The Vanguard Group | 3,835,758 6.740% |
3,835,758 (New Position) |
Filing |